Fluorocoxib A Encapsulation in ROS-Responsive Nanoparticles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge lies in developing new formulations for cyclooxygenase-2 (COX-2)-selective therapeutic and diagnostic agents like Fluorocoxib A (FA), which face solubility issues in aqueous solutions necessary for human administration, leading to poor pharmacokinetics and limited distribution to target tissues due to hydrophobicity and rapid renal clearance.
Innovation Solution
The development of ROS-responsive nanoparticles, specifically poly(propylene sulfide)-b-poly[oligo(ethylene glycol) methyl ether acrylate] (PPS106-b-POEGA17), that encapsulate FA, allowing for targeted delivery and release in response to oxidative stress, enhancing solubility and tissue specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If Fluorocoxib A is administered in DMSO or mixed solvents, then solubility is improved, but safety and suitability for human administration deteriorates
Solution Approach 1:
The patent uses ROS-responsive nanoparticles as an intermediary carrier to deliver Fluorocoxib A. The nanoparticle formulation allows the drug to be administered in aqueous solutions suitable for human use, eliminating the need for toxic DMSO or mixed solvents while maintaining solubility through encapsulation within the nanoparticle structure.
2Weight of moving object
If FA is administered as a small molecule, then molecular weight is low, but renal clearance increases leading to poor pharmacokinetics
Solution Approach 1:
The patent embeds the small molecule Fluorocoxib A within ROS-responsive nanoparticles. This nesting approach increases the effective molecular size to avoid renal clearance while maintaining the pharmacological activity of the core drug molecule. The nanoparticle carrier protects the small molecule from rapid elimination.
3Object-affected harmful factors
If FA is administered in aqueous solution, then biocompatibility is improved, but solubility deteriorates due to hydrophobicity
Solution Approach 1:
The patent changes the physical state and solubility parameters of Fluorocoxib A by incorporating it into nanoparticle formulations. The nanoparticle system transforms the hydrophobic small molecule into a colloidal suspension with improved aqueous solubility and biocompatibility, enabling effective delivery in physiological conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively targets and visualizes COX-2 in inflammatory and cancerous tissues with high specificity and retention, overcoming solubility barriers and improving pharmacokinetics, as demonstrated by increased fluorescence in inflamed and tumor tissues without significant accumulation in normal tissues.
Implementation Method 1
ROS-responsive nanoparticles, specifically poly(propylene sulfide)-b-poly[oligo(ethylene glycol) methyl ether acrylate] (PPS106-b-POEGA17), that encapsulate FA
Implementation Method 2
allowing for targeted delivery and release in response to oxidative stress
Implementation Method 3
Fluorocoxib A (FA), a fluorescent 5-carboxy-X-rhodamine-(5-ROX)-labeled COX-2-selective inhibitor
Data Source
AI summary
Disclosed are compositions that comprise a cyclooxygenase-2-selective therapeutic and/or diagnostic agent having a therapeutic and/or diagnostic agent conjugated to a NSAID drug; and a ROS-responsive nanoparticle. Methods of making and using these compositions for drug encapsulation and delivery are also disclosed.